[Follow-up of breast cancer patients by general practioner].

Related Articles

[Follow-up of breast cancer patients by general practioner].

Rev Med Brux. 2018;39(4):280-286

Authors: Veys I

Abstract
In Belgium, breast cancer is the most frequent women's cancer accounting for to 35.3 % of the cases. In 2013, 10,778 newly diagnosed breast cancers have been reported in Belgium. Breast cancer has a relatively good prognosis with a 5 year overall survival of 88 %. Survival will be different regarding the subtype and stage at diagnosis. The review of the literature and the guidelines from ESMO and ASCO regarding the follow-up of patients with early breast cancer will be used as references. International guidelines recommend clinical visits (frequencies depending of the subtypes of breast cancer) with an annual mammography associated with an echography. MRI Imaging should be performed in " at risk " patients. A more extensive exploration should be proceede when a relapse is suspected during follow up. Indeed, studies have shown that intensive follow- up with several additional exams detect more recurrences without any impact on overall survival and lead to anxiety. The follow-up of patients treated for breast cancer has several objectives : - Detect a local recurrence or a second tumor ; - Diagnosis of a distant relapse ; - Detect side effects of treatment ; - Psycho-social impact of the disease and improve the quality of life.

PMID: 30320989 [PubMed - in process]

Loading...

[Follow-up of breast cancer patients by general practioner].

Related Articles

[Follow-up of breast cancer patients by general practioner].

Rev Med Brux. 2018;39(4):280-286

Authors: Veys I

Abstract
In Belgium, breast cancer is the most frequent women's cancer accounting for to 35.3 % of the cases. In 2013, 10,778 newly diagnosed breast cancers have been reported in Belgium. Breast cancer has a relatively good prognosis with a 5 year overall survival of 88 %. Survival will be different regarding the subtype and stage at diagnosis. The review of the literature and the guidelines from ESMO and ASCO regarding the follow-up of patients with early breast cancer will be used as references. International guidelines recommend clinical visits (frequencies depending of the subtypes of breast cancer) with an annual mammography associated with an echography. MRI Imaging should be performed in " at risk " patients. A more extensive exploration should be proceede when a relapse is suspected during follow up. Indeed, studies have shown that intensive follow- up with several additional exams detect more recurrences without any impact on overall survival and lead to anxiety. The follow-up of patients treated for breast cancer has several objectives : - Detect a local recurrence or a second tumor ; - Diagnosis of a distant relapse ; - Detect side effects of treatment ; - Psycho-social impact of the disease and improve the quality of life.

PMID: 30320989 [PubMed - in process]

Loading...

Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care.

Icon for Atypon Related Articles

Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care.

Integr Cancer Ther. 2018 Oct 10;:1534735418801528

Authors: Maimon Y, Samuels N, Cohen Z, Berger R, Rosenthal DS

Abstract
BACKGROUND AND PURPOSE: LCS101 is a botanical formula extracted from 14 botanical components. While conventional oncology focuses on targeted medicine, research on LCS101 adopts a multi-targeted approach, examining its preclinical (in vitro, in vivo, and ex vivo) and clinical (randomized controlled trial, pragmatic) effects. This includes examining the formula's impact on the immune system, selective anticancer effects, and improved chemotherapy-related symptoms and quality of life. Effects on the Immune System: In murine splenic cell cultures, LCS101 significantly increased T-cell proliferation and macrophage tumor necrosis factor-α production. Blood samples from healthy volunteers exposed to LCS101 showed a dose-dependent increase in natural killer cell activity; and a randomized controlled trial showed significantly lower rates of leucopenia/neutropenia and anemia in patients with breast cancer undergoing chemotherapy. Selective Anticancer Effects: In vitro LCS101 demonstrated selective growth inhibition (on XTT viability assay) in human breast and prostate cancer cell lines, without any harmful effects on normal human epithelial cells. The anticancer effects were attributed to reactive oxygen species activity. Cytotoxic effects of doxorubicin and 5-fluorouracil on breast cancer cell lines were significantly increased following exposure to LCS101, with a protective effect in normal cells. Symptom Relief and Quality of Life: Clinical research shows that patients taking LCS101 during chemotherapy are less likely to report symptoms such as fatigue, pain, nausea and vomiting.
CONCLUSION: LCS101 exhibits multi-targeted effects, with significant implications for cancer care. Further research is needed to better understand the impact of these findings.

PMID: 30303021 [PubMed - as supplied by publisher]

Loading...